Table 3 Clinical characteristics of patients with and without MACCE in female PCI group
From: Improvement of long-term clinical outcomes by successful PCI in the very elderly women with ACS
Variables | MACCE group (n = 56) | Without MACCE group (n = 176) | P value |
|---|---|---|---|
Demographic | |||
 Age (years) | 83 (81, 84) | 82 (81, 84) | 0.188 |
 BMI (kg/m2) | 24.3 (22.5, 26.5) | 24.5 (22.3, 27.0) | 0.461 |
Past medical history | |||
 Hypertension, n (%) | 45 (80.4) | 140 (79.5) | 0.895 |
 Diabetes mellitus, n (%) | 18 (32.1) | 74 (42.0) | 0.187 |
 Dyslipidemia, n (%) | 21 (37.5) | 75 (42.6) | 0.499 |
 Prior MI, n (%) | 2 (3.6) | 15 (8.5) | 0.216 |
 Prior stroke, n (%) | 13 (23.2) | 43 (24.4) | 0.853 |
 Smoking, n (%) | 4 (7.1) | 19 (10.8) | 0.426 |
Clinical diagnosis | |||
 UAP, n (%) | 15 (26.8) | 96 (54.5) | < 0.001 |
 Non-STEMI, n (%) | 16 (29.1) | 39 (22.2) | 0.326 |
 STEMI, n (%) | 25 (44.6) | 41 (23.3) | 0.002 |
Length of stay (days) | 8 (6, 10) | 7 (6, 10) | 0.513 |
Laboratory finding | |||
 HbA1c (%) | 6.2 (5.6, 6.9) | 6.2 (5.7, 7.3) | 0.308 |
 TC (mmol/L) | 4.2 (3.6, 5.3) | 4.4 (3.7, 5.1) | 0.589 |
 LDL-C (mmol/L) | 2.40 (1.88, 3.24) | 2.49 (2.02, 2.94) | 0.738 |
 TG (mmol/L) | 1.3 (0.92, 1.84) | 1.3 (0.98, 1.89) | 0.555 |
 Creatinine (umol/L) | 81.3 (71, 101.6) | 74.2 (65.8, 89.1) | 0.029 |
 ALT (U/L) | 18 (10, 31) | 14 (10, 20) | 0.036 |
 CK-MB (ng/ml) | 2.1 (1.1, 8.1) | 1.7 (1.0, 3.7) | 0.071 |
 Log NT-proBNP | 3.23 (2.87, 3.71) | 2.83 (2.47, 3.30) | < 0.001 |
 LVEF ≥ 50%, n (%) | 39 (72.2) | 158 (91.9) | < 0.001 |
TIMI bleeding, n (%) | |||
 Major | 7 (12.5) | 8 (4.5) | 0.035 |
 Non-major | 6 (10.7) | 30 (17) | 0.254 |
Medication during follow up, n (%) | |||
 Aspirin | 40 (71.4) | 149 (84.7) | 0.026 |
 P2Y12 receptor antagonist* | 45 (80.4) | 170 (96.6) | < 0.001 |
 β-blocker | 24 (42.9) | 116 (65.9) | 0.002 |
 ACEI/ARB | 23 (41.1) | 89 (50.6) | 0.215 |
 Statin | 43 (76.8) | 153 (86.9) | 0.068 |